EMEA-001202-PIP02-13-M02

Key facts

Invented name
Cinqaero
Active substance
Reslizumab
Therapeutic area
Pneumology-allergology
Decision number
P/0010/2018
PIP number
EMEA-001202-PIP02-13-M02
Pharmaceutical form(s)
  • Concentrate for solution for infusion
  • Solution for injection
Condition(s) / indication(s)
Treatment of asthma
Route(s) of administration
  • Intravenous use
  • Subcutaneous use
Contact for public enquiries
Teva Pharmaceuticals Europe
Tel. +44 (0)20 7540 7117
E-mail: medinfo@tevauk.com
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating